Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04923867 · ClinicalTrials.gov registry record
Suturable DuraGen™ PMCF Study
A clinical trial, sponsored by Integra LifeSciences Corporation.
- Completed
- Registry status
- 106
- Enrollment target
NCT04923867: Completed study, sponsored by Integra LifeSciences Corporation.
NCT04923867 is a clinical trial that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 106 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04923867 has completed, sponsored by Integra LifeSciences Corporation.
- COMPLETED
- Registry status
- 106 participants
- Enrollment target
Study Summary
The primary goal of this study is to retrospectively collect data on the safety and efficacy of Suturable DuraGen™.
Primary Outcome
Occurrence of post-operative cerebrospinal fluid (CSF) leaks post-procedure
Interventions
- DEVICE Suturable DuraGen™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2024-07-31 |
What the finished NCT04923867 record still lists
NCT04923867 is an observational study that tracks outcomes without assigning an intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Suturable DuraGen™ is the first listed.
NCT04923867 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04923867 about?
NCT04923867 is a clinical study titled "Suturable DuraGen™ PMCF Study". The primary goal of this study is to retrospectively collect data on the safety and efficacy of Suturable DuraGen™.
What is the current status of trial NCT04923867?
This trial is currently completed. The enrollment target is 106 participants. The study started on 2021-04-28. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT04923867?
The interventions under investigation include: Suturable DuraGen™ (DEVICE).
Who is sponsoring clinical trial NCT04923867?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI